A Phase 1/2a Study Evaluating the Effects of ARO-RAGE Inhalation Solution in Healthy Subjects and Patients With Inflammatory Lung Disease
Latest Information Update: 27 May 2025
At a glance
- Drugs ARO-RAGE (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors Arrowhead Pharmaceuticals
Most Recent Events
- 18 May 2025 Status changed from active, no longer recruiting to completed.
- 08 Jan 2025 Planned End Date changed from 1 Feb 2025 to 1 Mar 2025.
- 08 Jan 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Mar 2025.